CLSA Starts Asahi Kasei at Outperform With 1,300 Yen Price Target
Maintaining Hold Rating Amidst Calliditas Acquisition by Asahi Kasei: Assessing the Premium Offer and Strategic Fit
Asahi Kasei's Acquisition of Calliditas Therapeutics: A Hold Rating With Revised Price Target
No Data
No Data